The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer
Open accessAbstract
The transcription factor NRF2 is a master regulator of the cellular antioxidant response, and it is often genetically activated in non-small-cell lung cancers (NSCLCs) by, for instance, mutations in the negative regulator KEAP1. While direct pharmacological inhibition of NRF2 has proven challenging, its aberrant activation rewires biochemical networks in cancer cells that may create special vulnerabilities. Here, we use chemical proteomics to map druggable proteins that are selectively expressed in KEAP1-mutant NSCLC cells. Principal among these is NR0B1, an atypical orphan nuclear receptor that we show engages in a multimeric protein complex to regulate the transcriptional output of KEAP1-mutant NSCLC cells. We further identify small molecules that covalently target a conserved cysteine within the NR0B1 protein interaction domain, and we demonstrate that these compounds disrupt NR0B1 complexes and impair the anchorage-independent growth of KEAP1-mutant cancer cells. Our findings designate NR0B1 as a druggable transcriptional regulator that supports NRF2-dependent lung cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The authors discovered compounds that bind to a ligandable cysteine on the nuclear receptor NR0B1, which is regulated by NRF2, a substrate of KEAP1 (ref.181).”
From Advances in covalent drug discovery (2022) · cites this paper as [181]
In the citing paper
“cysteine reactivity and ligandable sites were mapped in mutant Kelch-like ECH-associated protein 1 (KEAP1) and compared with those in wild-type KEAP1 NSCLC lines.”
From Advances in covalent drug discovery (2022) · cites this paper as [181]
In the citing paper
“We finally observed limited overlap of enantioprobe targets with proteins that demonstrated ligandability in previous chemical proteomic studies using cysteine-26,27 or lysine-reactive28 electrophilic fragments (Fig. 3b)”
From Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs (2019) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · cited 1×
“Cancer cells rewire central metabolic networks to provide a steady source of energy and building blocks needed for cell division and rapid growth (Possemato et al., 2011; Vander Heiden et al., 2009).”
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579 · cited 7×
“This demand for energy produces toxic metabolic by-products, including reactive oxygen species (ROS), that, if left unchecked, can promote oxidative stress and impair cancer cell viability (Gorrini et al., 2013; Schafer et al., 2009).”
InfluentialSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 264
Huebbers, C. U., Verhees, F., Poluschkin, L., Olthof, N. C., Kolligs, J., Siefer, O. G., Henfling, M. E. R., Ramaekers, F. C. S., Preuss, S. F., Beutner, D., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31954 · Cited by 38
“Low risk groups can then profit from de-intensification of treatment protocols,(41) whereas intermediate and high risk groups could be selected for other therapeutic options, such as inhibitors of the PI3K and NRF2 pathways including the AKR1C proteins.(17,42,43) Potential treatment options addressing oxidative stress…”
Ji, K.-Y., Liu, C., Liu, Z., Deng, Y., Hou, T., & Cao, D. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad014 · Cited by 40
Proteomic Approaches to Study SARS-CoV-2 Biology and COVID-19 Pathology
Haas, P., Muralidharan, M., Krogan, N. J., Kaake, R. M., & Hüttenhain, R. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00764 · Cited by 40
Chemical proteomics for subcellular proteome analysis
Zhu, H., Tamura, T., & Hamachi, I. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.08.001 · Cited by 37
Chemical Proteomics Reveals Antibiotic Targets of Oxadiazolones in MRSA
Bakker, A. T., Kotsogianni, I., Mirenda, L., Straub, V. M., Ávalos, M., van den Berg, R. J. B. H. N., Florea, B. I., van Wezel, G. P., Janssen, A. P. A., Martin, N. I., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10819 · Cited by 35
Ogasawara, D., Konrad, D. B., Tan, Z. Y., Carey, K. L., Luo, J., Won, S. J., Li, H., Carter, T. R., DeMeester, K. E., Njomen, E., et al. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.10.005 · Cited by 31
Self-citationYan, T., Palmer, A. B., Geiszler, D., Polasky, D. A., Boatner, L. M., Burton, N. R., Armenta, E., Nesvizhskii, A. I., & Backus, K. M. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04402 · Cited by 32
Self-citationKey Considerations in Targeted Protein Degradation Drug Discovery and Development
Qin, L., Dai, H., & Wang, J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.934337 · Cited by 35
Proteome‐Wide Fragment‐Based Ligand and Target Discovery
Forrest, I., & Parker, C. G. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202200098 · Cited by 31
Activity‐Based Protein Profiling – Finding General Solutions to Specific Problems
Cravatt, B. F. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202300029 · Cited by 31
Self-citationThe mechanistic insights of the antioxidant Keap1-Nrf2 pathway in oncogenesis: a deadly scenario
Mukherjee, A. G., & Gopalakrishnan, A. V. (2023) · Medical Oncology · doi:10.1007/s12032-023-02124-4 · Cited by 33
NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting
Panda, H., Rowland, N. G., Krall, C. M., Bowman, B. M., Major, M. B., & Zolkind, P. (2025) · Oncogene · doi:10.1038/s41388-025-03560-4 · Cited by 39
Koo, T.-Y., Lai, H., Nomura, D. K., & Chung, C. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-39268-w · Cited by 35
Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs
Petrek, H. E., Batra, N., Ho, P. Y., Tu, M., & Yu, A. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09934-5 · Cited by 31
Rabalski, A. J., Bogdan, A. R., & Baranczak, A. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00424 · Cited by 30
Widespread, Reversible Cysteine Modification by Methylglyoxal Regulates Metabolic Enzyme Function
Coukos, J. S., Lee, C. W., Pillai, K. S., Liu, K. J., & Moellering, R. E. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00727 · Cited by 30
A new era of cysteine proteomics – Technological advances in thiol biology
Burger, N., & Chouchani, E. T. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102435 · Cited by 30
Robust proteome profiling of cysteine-reactive fragments using label-free chemoproteomics
Biggs, G. S., Cawood, E. E., Vuorinen, A., McCarthy, W. J., Wilders, H., Riziotis, I. G., van der Zouwen, A. J., Pettinger, J., Nightingale, L., Chen, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55057-5 · Cited by 36
“To focus on the most robust liganding events in each screen, we performed strict peptide fi ltering and have de fi ned liganded peptides as those with statistically signi fi cant competition of at least 50% (log 2 (CR) ≥ 1.0, -log 10 ( p -value) ≥ 1.3).”
InfluentialDarabedian, N., Chen, T. C., Molina, H., Pratt, M. R., & Schönthal, A. H. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00743 · Cited by 29
Chemical Biology Tools for Protein Lysine Acylation
Xie, Y., Du, S., Liu, Z., Liu, M., Xu, Z., Wang, X., Kee, J. X., Yi, F., Sun, H., & Yao, S. Q. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202200303 · Cited by 29
Organic Selenium induces ferroptosis in pancreatic cancer cells
Noè, R., Inglese, N., Romani, P., Serafini, T., Paoli, C., Calciolari, B., Fantuz, M., Zamborlin, A., Surdo, N. C., Spada, V., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102962 · Cited by 30
“While this promotes carcinogenesis through multiple mechanisms, including cysteine/methionine oxidation [2,3], genomic instability [4] and altered stromal interactions [5], cancer cells carefully control ROS levels to avoid the accumulation of toxic species.”
Fan, Y., Si, H., Zhang, Z., Zhong, L., Sun, H., Zhu, C., Yin, Z., Li, H., Tang, G., Yao, S. Q., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02024 · Cited by 29
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
Ooki, A., Osumi, H., Chìn, K., Watanabe, M., & Yamaguchi, K. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221138377 · Cited by 28
CellFy: A Cell-Based Fragment Screen against C-Type Lectins
Schulze, J., Baukmann, H. A., Wawrzinek, R., Fuchsberger, F. F., Specker, E., Aretz, J., Nazaré, M., & Rademacher, C. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00875 · Cited by 27
Cai, M., Chen, M., Ma, P., Wu, J., Lu, H., Zhang, S., Liu, J., Zhao, X., Zhuang, G., Yu, Z., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31975 · Cited by 25
Zhou, Y., Shen, W., Peng, J., Deng, Y., & Li, X. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116328 · Cited by 24
Wang, T., Ma, S., Ji, G., Wang, G., Liu, Y., Zhang, L., Zhang, Y., & Lu, H. (2024) · Nature Communications · doi:10.1038/s41467-024-47033-w · Cited by 27
Leahy, C., Osborne, N., Shirota, L., Rote, P., Lee, Y., Song, B., Yin, L., Zhang, Y., Garcia, V. G., & Hardwick, J. P. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116241 · Cited by 23
Delineating cysteine-reactive compound modulation of cellular proteostasis processes
Julio, A. R., Shikwana, F., Truong, C. C., Burton, N. R., Dominguez, E. R., Turmon, A. C., Cao, J. X., & Backus, K. M. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01760-9 · Cited by 23
“Cell-based chemoproteomic screening using low-mid-micromolar concentrations (for example, 10–50 µm) of covalent compounds, such as the molecules reported by our study, is an increasingly common strategy for target hunting 2,5,7,28,30,66,79,80–85 .”
Self-citationAn allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes
Zhang, Y., Liu, Z., Hirschi, M., Brodsky, O., Johnson, E., Won, S. J., Nagata, A., Bezwada, D., Petroski, M. D., Majmudar, J. D., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01738-7 · Cited by 27
Self-citationNeocarzilin A Is a Potent Inhibitor of Cancer Cell Motility Targeting VAT-1 Controlled Pathways
Gleissner, C. M.-L., Pyka, C. L., Heydenreuter, W., Gronauer, T. F., Atzberger, C., Korotkov, V. S., Cheng, W., Hacker, S. M., Vollmar, A. M., Braig, S., et al. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00266 · Cited by 21
Pirin, an Nrf2-Regulated Protein, Is Overexpressed in Human Colorectal Tumors
Zhang, Y., Knatko, E. V., Higgins, M., Naidu, S. D., Smith, G. C., Honda, T., de la Vega, L., & Dinkova‐Kostova, A. T. (2022) · Antioxidants · doi:10.3390/antiox11020262 · Cited by 21
“A chemical proteomics approach suggested pirin as one of the proteins regulated by Nrf2 in non-small cell lung cancer cell lines [10].”
Targeting the ubiquitin system by fragment-based drug discovery
Kennedy, C. R., McPhie, K. A., & Rittinger, K. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1019636 · Cited by 21
“A novel method, using broadly reactive electrophilic scout fragments (Backus et al., 2016; Bar-Peled et al., 2017) as E3 ligase recruiters in PROTAC molecules, identified two novel CRL4 E3 ligases, DCAF16 and DCAF11, for TPD purposes.”
Chatterjee, N., & Bohmann, D. (2018) · BioEssays · doi:10.1002/bies.201800007 · Cited by 21
Opportunities and challenges for the development of covalent chemical immunomodulators
Backus, K. M., Cao, J. X., & Maddox, S. M. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.05.050 · Cited by 21
Self-citationLi, J., Yu, Z., Choo, S., Zhao, J., Wang, Z., & Xie, R. (2020) · ACS Omega · doi:10.1021/acsomega.0c01275 · Cited by 20
Jung, Y., Noda, N., Takaya, J., Abo, M., Toh, K., Tajiri, K., Cui, C., Zhou, L., Sato, S., & Uesugi, M. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00824 · Cited by 20
Yang, C., Bao, S., Wang, Z., Fang, Z., & Tang, H. (2024) · European journal of medical research · doi:10.1186/s40001-024-01930-4 · Cited by 22
“…which will help to improve the therapeutic efficacy of DDP. Studies reported that large amounts of reactive oxygen species (ROS) accumulate in cancer cells to meet their demands for rapid growth and reconnection of metabolic networks due to abnormal metabolism and signal transduction [5].”
Cysteine modifiers suggest an allosteric inhibitory site on the CAL PDZ domain
Zhao, Y., Cushing, P. R., Smithson, D. C., Pellegrini, M., Pletnev, A. A., Al-Ayyoubi, S., Grassetti, A. V., Gerber, S. A., Guy, R. K., & Madden, D. R. (2018) · Bioscience Reports · doi:10.1042/bsr20180231 · Cited by 19
Budayeva, H. G., Ma, T. P., Wang, S., Choi, M., & Rose, C. M. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00598 · Cited by 19
Rocca, A., Crinò, L., Braga, L., Salton, F., Ruaro, B., Confalonieri, M., Generali, D., & Confalonieri, P. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03139-6 · Cited by 24
Hall, D. R., & Peng, H. (2020) · Comparative Biochemistry and Physiology Part D Genomics and Proteomics · doi:10.1016/j.cbd.2020.100655 · Cited by 18
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins
Zhang, X., & Cravatt, B. F. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-041946 · Cited by 19
Self-citationCovalent targeting of splicing in T cells
Scott, K. A., Kojima, H., Ropek, N., Warren, C. D., Zhang, T. L., Hogg, S. J., Sanford, H., Webster, C. G., Zhang, X., Rahman, J. A., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.10.010 · Cited by 16
Self-citationPerspective on the Structural Basis for Human Aldo-Keto Reductase 1B10 Inhibition
Ruiz, F. X., Parés, X., & Farrés, J. (2021) · Metabolites · doi:10.3390/metabo11120865 · Cited by 17
“They have developed powerful chemical proteomics approaches to map Cys ligandability in mammalian cancer cell lines [37].”
Jia, H., Brixius, B., Bocianoski, C., Ray, S., Koes, D. R., & Brixius‐Anderko, S. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001463 · Cited by 17
Discovery of GPX4 inhibitors through FP-based high-throughput screening
Cao, Y., Wu, B., Xu, Y., Wang, M., Wu, X., Liang, X., Lin, J., Li, Z., Lin, H., Luo, C., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116044 · Cited by 18
Bracken, A. K., Gekko, C. E., Suss, N. O., Lueders, E. E., Cui, Q., Fu, Q., Lui, A. C. W., Anderson, E. T., Zhang, S., & Abbasov, M. E. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c10741 · Cited by 16
Ocaña, M. C., Bernal, M., Yang, C., Caro, C., Domínguez, A., Vu, H., Cárdenas, C., García‐Martín, M. L., DeBerardinis, R. J., Quesada, A. R., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05443-4 · Cited by 16
BNIP3 Upregulation Characterizes Cancer Cell Subpopulation With Increased Fitness and Proliferation
Zhu, Y., Chen, B., Yan, J., Zhao, W., Dou, P., Sun, N., Wang, Y., & Huang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.923890 · Cited by 15
Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets
Lee, J., & Park, S. B. (2022) · Pharmaceuticals · doi:10.3390/ph15121478 · Cited by 16
Reactive Oxygen Species, Cellular Redox Homeostasis and Cancer
Mydin, R. B. S. M. N., & Okekpa, S. I. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.76096 · Cited by 17
“Therefore, ROS can act both as good and bad molecules because of their dual nature and can either induce regulation of cellular physiology or promote the induction of cytotoxicity depending on generation levels, site of generation and magnitude of generation [9].”
Development of targeted therapy of NRF2high esophageal squamous cell carcinoma
Paiboonrungruang, C., Simpson, E., Xiong, Z., Huang, C. D., Li, J., Li, Y., & Chen, X. L. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110105 · Cited by 15
Ramsey, J. R., Shelton, P. M. M., Heiss, T. K., Olinares, P. D. B., Vostal, L. E., Soileau, H., Grasso, M. J., Casebeer, S. W., Adaniya, S. M., Miller, M., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c10581 · Cited by 16
Self-citationChemoproteogenomic stratification of the missense variant cysteinome
Desai, H. S., Andrews, K. H., Bergersen, K. V., Ofori, S., Yu, F., Shikwana, F., Arbing, M. A., Boatner, L. M., Villanueva, M., Ung, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53520-x · Cited by 24
Self-citationNazari, A., Osati, P., Fakhr, S. S., Faghihkhorasani, F., Ghanaatian, M., Faghihkhorasani, F., Rezaei‐Tazangi, F., Far, N. P., Shourideh, A., Ebrahimi, N., et al. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0491 · Cited by 13
Lv, S., Xu, F., Fan, Y., Ding, K., & Li, Z. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01889 · Cited by 13
Systematic Identification of Multi Omics-based Biomarkers in KEAP1 Mutated TCGA Lung Adenocarcinoma
Namani, A., Zheng, Z.-H., Wang, X. J., & Tang, X. (2019) · Journal of Cancer · doi:10.7150/jca.35489 · Cited by 13
“We also retrieved the publicly available RNA-Seq results of NRF2 knockdown (NRF2 KD) LUAD cell lines such as A549 from Olagnier et al, 2018 (GSE113519) [16] and H2122 from Bar-Peled et al, 2017 (GSE89569) [17] to cross check the expression pattern of KMSGC.”
Metabolic Phenotypes, Dependencies, and Adaptation in Lung CancerPreprint
DeNicola, G. M., & Shackelford, D. B. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037838 · Cited by 13
Liao, Y., Chan, S. C., Welsh, E. A., Fang, B., Sun, L., Schönbrunn, E., Koomen, J. M., Duckett, D. R., Haura, E. B., Monastyrskyi, A., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00587 · Cited by 12
Chemical proteomic mapping of reversible small molecule binding sites in native systems
Wozniak, J. M., Li, W., & Parker, C. G. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.09.001 · Cited by 15
Proteome-Wide Covalent Targeting of Acidic Residues with Tunable N -Aryl Aziridines
Qiu, N., Tan, H., Pechalrieu, D., Abegg, D., Fnu, D., Mukherjee, P., Rentería‐Gómez, Á., Gutiérrez, O., Powers, D. C., & Adibekian, A. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c04685 · Cited by 12
Guan, I. A., Williams, K., Pan, J., & Liu, X. (2021) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202100036 · Cited by 13
Pharmacological Modulation of Transcriptional Coregulators in Cancer
Bishop, T. R., Zhang, Y., & Erb, M. A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.004 · Cited by 11
Reactive oxygen species and cancer
Kong, H., & Chandel, N. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818606-0.00030-4 · Cited by 12
Rothweiler, E. M., Brennan, P. E., & Huber, K. (2022) · Biological Chemistry · doi:10.1515/hsz-2021-0396 · Cited by 12
The Proteome‐Wide Potential for Reversible Covalency at Cysteine
Senkane, K., Vinogradova, E. V., Suciu, R. M., Crowley, V. M., Zaro, B. W., Bradshaw, J. M., Brameld, K. A., & Cravatt, B. F. (2019) · Angewandte Chemie · doi:10.1002/ange.201905829 · Cited by 16
Self-citationTargeting extrachromosomal DNA in human cancers
Wong, I. T.-L., Yi, H., Melillo, B. N., Cravatt, B. F., Chang, H. Y., & Mischel, P. S. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01369-0 · Cited by 12
Self-citationProteome-Wide Discovery of Degradable Proteins Using Bifunctional Molecules
Forrest, I., Conway, L. P., Gathmann, C., Jadhav, A. M., Chiu, T.-Y., Chaheine, C. M., Estrada, M. A., Shrestha, A., Sarris, K., Reitsma, J. M., et al. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c01594 · Cited by 12
Quantitative Chemoproteomic Methods for Reactive Cysteinome Profiling
Xiao, W., Chen, Y., & Wang, C. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202200100 · Cited by 12
Advances in the application of proteomics in lung cancer
Bai, L., Zhang, Z., Xiang, Z., Cai, Y., Zhang, X., & Wu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.993781 · Cited by 11
“Nuclear receptor NR0B1 was identified as a potential druggable molecule for lung cancer dependent on the transcription factor NRF2 (74).”
Multi-omic stratification of the missense variant cysteinomePreprint
Desai, H. S., Ofori, S., Boatner, L. M., Yu, F., Villanueva, M., Ung, N., Nesvizhskii, A. I., & Backus, K. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.12.553095 · Cited by 11
Self-citationBest Practices for Design and Characterization of Covalent Chemical Probes
Gabizon, R., Resnick, E., & London, N. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160745-00069 · Cited by 10
Proteomic Ligandability Maps of Phosphorus(V) Stereoprobes Identify Covalent TLCD1 Inhibitors
Sharma, H. A., Bielecki, M., Holm, M. A., Thompson, T. M., Yin, Y., Cravatt, J. B., Ware, T. B., Reed, A., Nassir, M., Ewing, T. E., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c01944 · Cited by 11
Self-citationBonus, M., Greb, J., Majmudar, J. D., Boehm, M., Korczynska, M., Nazemi, A., Mathiowetz, A. M., & Gohlke, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169196 · Cited by 12
High‐Throughput Kinetic Analysis for Target‐Directed Covalent Ligand Discovery
Craven, G. B., Affron, D. P., Allen, C. E., Matthies, S., Greener, J. G., Morgan, R. M. L., Tate, E. W., Armstrong, A., & Mann, D. J. (2018) · Angewandte Chemie · doi:10.1002/ange.201711825 · Cited by 10
Vinyl sulfonamide synthesis for irreversible tethering via a novel α-selenoether protection strategy
Craven, G. B., Affron, D. P., Raymond, P. N., Mann, D. J., & Armstrong, A. (2018) · MedChemComm · doi:10.1039/c8md00566d · Cited by 10
Comprehensive Mapping of Electrophilic Small Molecule-Protein Interactions in Human CellsPreprint
Cravatt, B. F., Njomen, E., Hayward, R., DeMeester, K. E., Ogasawara, D., Dix, M. M., Nguyen, T., Ashby, P., Simon, G. M., Schreiber, S. L., et al. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-s446n · Cited by 9
Self-citationJulio, A. R., Shikwana, F., Truong, C. C., Burton, N. R., Dominguez, E. R., Turmon, A. C., Cao, J. X., & Backus, K. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.30.564067 · Cited by 8
Self-citationChen, Z., Yu, M. G., Li, Z.-Y., Zheng, L.-L., Zhang, J., Liu, T.-T., Yang, Z., Li, L., Lu, Z., Wei, T., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c21740 · Cited by 8
Tracking Pathogen Infections by Time‐Resolved Chemical Proteomics
Zhang, Y., Kao, D., Gu, B., Bomjan, R., Srivastava, M., Lu, H., Zhou, D., & Tao, W. A. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201911078 · Cited by 8
Zhang, W., Li, Y., Chen, S., Zhang, C., Chen, L., & Peng, G. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.08.019 · Cited by 9
Schipper, S., Wu, H., Furdui, C. M., Poole, L. B., Delahunty, C. M., Park, S. K. R., Yates, J. R., Becker, K., & Przyborski, J. M. (2021) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2021.111362 · Cited by 8
Chemical proteomic identification of functional cysteines with atypical electrophile reactivities
Litwin, K. M., Crowley, V. M., Suciu, R. M., Boger, D. L., & Cravatt, B. F. (2021) · Tetrahedron Letters · doi:10.1016/j.tetlet.2021.152861 · Cited by 9
Self-citationSmall molecule inhibitors for cancer metabolism: promising prospects to be explored
Liu, D., Wang, H., Li, X., Liu, J., Zhang, Y., & Hu, J. Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04501-4 · Cited by 7
Liao, Y., Weng, J., Chen, L., Hu, N., Yuan, X., Wang, J., He, F., Cai, Y., Huang, Q., Wang, J., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.911378 · Cited by 7
“CXCL8, FABP6, and NR0B1 promote tumor growth in LIHC (Bar-Peled et al., 2017; Zhang et al., 2019b; Sun et al., 2019; Huang et al., 2015).”
Conditional Covalent Lethality Driven by Oncometabolite Accumulation
Perez, M., Nance, K. D., Bak, D. W., Gamage, S. T., Najera, S. S., Conte, A. N., Linehan, W. M., Weerapana, E., & Meier, J. L. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00384 · Cited by 6
A Personal Perspective on Chemical Biology: Before the Beginning
Dervan, P. B. (2019) · Israel Journal of Chemistry · doi:10.1002/ijch.201800171 · Cited by 7
Chagas, B. C. A., Jia, H., Brixius, B., & Brixius‐Anderko, S. (2025) · Open Biology · doi:10.1098/rsob.250115 · Cited by 6
“In 2017, it was reported that CYP4F11 is positively regulated by NRF2 in NSCLC [93].”
Dutta, S., Ghosh, S., Mishra, A. B., & Ghosh, R. (2022) · Journal of Proteins and Proteomics · doi:10.1007/s42485-022-00100-6 · Cited by 6
Shikwana, F., Heydari, B. S., Ofori, S., Truong, C. C., Turmon, A. C., Darrouj, J., Holoidovsky, L., Gustafson, J. L., & Backus, K. M. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100898 · Cited by 8
Self-citationChemical Biology Tools for Protein Lysine Acylation
Xie, Y., Du, S., Liu, Z., Liu, M., Xu, Z., Wang, X., Kee, J. X., Yi, F., Sun, H., & Yao, S. Q. (2022) · Angewandte Chemie · doi:10.1002/ange.202200303 · Cited by 6
Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite
Perez, M., Bak, D. W., Bergholtz, S. E., Crooks, D. R., Arimilli, B. S., Yang, Y., Weerapana, E., Linehan, W. M., & Meier, J. L. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ac120.014993 · Cited by 6
Inducible Protein Degradation to Understand Genome Architecture
Tallan, A. M., & Stanton, B. Z. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00306 · Cited by 6
Unlocking DCAFs To Catalyze Degrader Development: An Arena for Innovative Approaches
Miao, Q., Kadam, V. D., Mukherjee, A., Tan, Z., & Teng, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01209 · Cited by 7
Hong, S. H., Xi, S. Y., Johns, A. C., Tang, L. C., Li, A., Hum, M. N., Chartier, C. A., Jovanović, M., & Shah, N. H. (2023) · ChemBioChem · doi:10.1002/cbic.202200706 · Cited by 5
Chemical proteomics to study metabolism, a reductionist approach applied at the systems level
Ali, M. Y., & Bar‐Peled, L. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.02.015 · Cited by 5
Self-citationLi, J., Wang, G., Ye, M., & Qin, H. (2023) · Chinese Journal of Chromatography · doi:10.3724/sp.j.1123.2022.05013 · Cited by 5
Zheng, Z., Cheng, Y., Li, P., & Tan, C. S. H. (2024) · ChemBioChem · doi:10.1002/cbic.202400715 · Cited by 4
An Unbiased Immunoaffinity-Based Strategy for Profiling Covalent Drug Targets In Vivo
Wang, X., Wang, X., Pu, X., Pu, W., Wang, Y., Liu, Y., Gong, Y., Jin, X., Peng, Y., & Dai, L. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b04118 · Cited by 4
Metadata
- Authors
- Bar-Peled, L., Kemper, E. K., Suciu, R. M., Vinogradova, E. V., Backus, K. M., Horning, B. D., Paul, T. A., Ichu, T.-A., Svensson, R. U., Olucha, J., Chang, M. W., Kok, B. P., Zhu, Z., Ihle, N. T., Dix, M. M., Jiang, P., Hayward, M. M., Saez, E., Shaw, R. J., & Cravatt, B. F.
- Affiliations
- Scripps Research Institute (US)
- Pfizer (United States) (US)
- Salk Institute for Biological Studies (US)
- University of California San Diego (US)
- Corresponding author
- Cravatt, Benjamin F.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 171
- Issue
- 3
- Pages
- 696-709.e23
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5728659
- OpenAlex
- W2757007104
- Cited by
- 262
- References
- 59
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 34 · 2023: 41 · 2022: 29 · 2021: 30 · 2020: 25 · 2019: 36 · 2018: 24 · 2017: 3
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- NIH (CA087660, CA132630, CA172229, CA215249-01, CA211526)
- NIH-NCI CCSG (P30 014195)
- Chapman Foundation
- Helmsley Charitable Trust
- Damon Runyon Cancer Research Foundation
- American Cancer Society
- Life Sciences Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- Nrf2, KEAP1 mutation, non-small cell lung cancer, NR0B1, orphan nuclear receptor, chemoproteomics, druggable vulnerabilities, covalent inhibitors, anchorage-independent growth, transcriptional regulation, antioxidant response
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Carcinoma, Non-Small-Cell Lung, Cysteine, Humans, Ligands, Lung Neoplasms, Proteome, Cell Line, Tumor, Gene Regulatory Networks, DAX-1 Orphan Nuclear Receptor, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
